Periodic Reporting for period 1 - STIMOS (Stimulation of Multiple Organoids Simultaneously)
Reporting period: 2019-09-02 to 2021-09-01
- A market study on light stimulation modules for use with microelectrode arrays.
- Development and testing of fully customizable stimulation hardware and software capable of inducing light mediated electrical activity in retina and 3D human retinal organoids.
- A tissue holder suitable for multi-well microelectrode array application.
- A multi-well LED based stimulation device, packaged in a multi-well platform compatible format.
MaxWell Biosystems is currently integrating the STIMOS prototype into a perfusion system.
MaxWell Biosystems is currently performing a customer survey, in order to learn how many laboratories plan to adopt STIMOS platform in the next 2 years.
STIMOS platform can record and identify retinal ganglion cell mosaics in a high throughput per well (>1000 RGCs per well). HD-MEA technology featured in STIMOS platform is particularly suited for recording retinal output due to (1) full accessibility of all neurons, (2) electrodes with the largest spike amplitude can be chosen for spike extraction (3) each neuron will have unique action potential spatial profile or distribution. STIMOS allows to classify retinal ganglion cell electrophysiological activity in human retinal organoids. Importantly, STIMOS enables scientists to test effectiveness of therapies for blindness and assess their of functionality in distinct classes of retinal ganglion cells types. Furthermore, STIMOS delivers accurate and multiparametric new datasets for machine learning and advanced algorithms. Long-term, this approach will allow to test and assess personalized eye therapies for vision diseases.